Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
03/2010
03/24/2010EP2164859A2 Methods and compositions involving polymeric immunoglobulin fusion proteins
03/24/2010EP2164516A1 Optimized dna and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
03/24/2010EP2164514A2 Antibodies to il-6 and use thereof
03/24/2010EP1755660B1 Method for enhancing or inhibiting insulin-like growth factor-i
03/24/2010EP1697403B1 Haemophilus influenzae type iv pili
03/24/2010EP1180938B1 Agents, compositions and methods utilizing the same useful in treating or preventing alzheimer disease
03/24/2010EP1075496B1 Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
03/24/2010EP1067962B1 Derivatives of pneumococcal choline binding proteins for vaccines
03/24/2010CN101680902A Cartilage intermediate layer protein 2 C1 and its use to differentiate osteoarthritis from rheumatoid arthritis and non-disease conditions
03/24/2010CN101680031A Methods of stratifying adolescent idiopathic scoliosis, isolated nucleic acid molecules for use in same and kits using same
03/24/2010CN101679974A Constructs and libraries comprising antibody surrogate light chain sequences
03/24/2010CN101679968A Polypeptide capable of improving tolerance to iron deficiency in plant, and use thereof
03/24/2010CN101679966A Genetically recombinant antibody composition having enhanced effector activity
03/24/2010CN101679528A Apoptotic anti-ige antibodies
03/24/2010CN101679527A Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
03/24/2010CN101679526A Humanized and chimeric anti-TROP-2 antibodies that mediate cancer cell cytotoxicity
03/24/2010CN101679525A Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
03/24/2010CN101679524A Inorxoclonal antibody directed against the human LDL receptor
03/24/2010CN101679523A Novel fully human anti-vap-1 monoclonal antibodies
03/24/2010CN101679522A Modulation of tumor microenvironment
03/24/2010CN101679521A Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
03/24/2010CN101679520A hutnfr1 selective antagonists
03/24/2010CN101679519A Antibodies to CD200R
03/24/2010CN101679517A Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
03/24/2010CN101679516A Antigen-binding proteins targeting s. aureus ORF0657
03/24/2010CN101679515A Novel human anti-r7v antibodies and uses thereof
03/24/2010CN101679514A A fusion polypeptide for detection of conserved combinatorial or composite epitopes in non-conserved proteins
03/24/2010CN101679513A Recombinant antibodies for treatment of respiratory syncytial virus infections
03/24/2010CN101679512A Human antibodies against hepatitis c virus (hcv) uses thereof
03/24/2010CN101679511A Polypeptides, antibody variable domains and antagonists
03/24/2010CN101679510A Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
03/24/2010CN101679509A immunoglobulin purification
03/24/2010CN101679508A Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells
03/24/2010CN101679507A crystalline anti-human il-12 antibodies
03/24/2010CN101679506A Compositions and methods for binding sphingosine-1-phosphate
03/24/2010CN101679501A methods of treating, diagnosing and detecting fgf21-associated disorders
03/24/2010CN101679481A Separation method using polymer multi phase systems
03/24/2010CN101678104A New indications for anti- il-i-beta therapy
03/24/2010CN101678103A antibody formulation
03/24/2010CN101678101A Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of B-chronic lymphocytic leukaemia
03/24/2010CN101678100A methods of treating systemic lupus erythematosus
03/24/2010CN101678093A Vaccine for the prevention of breast cancer relapse
03/24/2010CN101676728A cytokine receptor
03/24/2010CN101676301A Antibody for inhibitting growth of colorectal carcinoma and its use in preparation of medicament and kit
03/24/2010CN101676300A Antibody for inhibitting growth of colorectal carcinoma and its use in preparation of diagnostic agent of adenocarcinoma
03/24/2010CN100595212C Interleukin-10 antibodies
03/24/2010CN100595211C Angiopoietin-2 specific binding agents
03/24/2010CN100595210C Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use therof.
03/24/2010CN100594935C Antibodies that immunospecifically bind to trail receptors
03/24/2010CN100594932C Tumor necrosis factor antagonists and their use in endometriosis
03/23/2010US7683159 Tenascin-W compositions and uses thereof
03/23/2010US7683061 rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis; reduced drug toxicity
03/23/2010US7682794 Methods for detecting and analyzing N-glycolylneuraminic acid (Neu5Gc) in biological materials
03/23/2010US7682613 Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
03/23/2010US7682612 Chronic Lymphocytic Leukemia (CLL) is treated with antibodies directed against the CD20 antigen; rituximab; chemotherapy
03/23/2010US7682611 Chemokine receptor-4 (CXCR4) specific immunoglobulin for diagnosis, prevention and treatment of viral or bacterial infection
03/23/2010US7682610 Vascular endothelial growth factor receptor specific immunoglobulin for diagnosis, prevention and treatment of cell proliferative disorders
03/23/2010US7682609 lyophilized mixture of a recombinant humanized HER2 monoclonal antibody, a lyoprotectant, and a buffer; physical and chemical stability and integrity upon lyophilization and storage; breast cancer
03/23/2010US7682608 Stabilized preparations containing antibody
03/23/2010US7682607 Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
03/23/2010CA2389808C Antibodies to bis[sulfosuccinimidyl] suberate (bs3) or disuccinimidyl suberate (dss) as labels for proteins and nucleic acids
03/23/2010CA2356737C Tumor necrosis factor antagonists and their use in endometriosis
03/23/2010CA2290724C Glycopeptide hexapeptides
03/23/2010CA2236168C Disruption of expression of multiple alleles of mammalian genes
03/23/2010CA2203655C Tumor necrosis factor-gamma
03/18/2010WO2010030979A2 Targeting pathogenic monocytes
03/18/2010WO2010030840A2 Novel receptor and uses thereof
03/18/2010WO2010030813A2 Methods for inhibiting ocular angiogenesis
03/18/2010WO2010030687A1 Monoclonal antibodies specific for pancreatic neoplasia cells
03/18/2010WO2010030653A2 Nurr1 interacting protein (nuip)
03/18/2010WO2010030641A2 Pancreatic cancer markers
03/18/2010WO2010030203A1 Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
03/18/2010WO2010030182A2 Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
03/18/2010WO2010030178A1 Lcms technology and its uses
03/18/2010WO2010029534A1 Antibody combinations and use of same for treating cancer
03/18/2010WO2010029497A1 Treatment of endometriosis
03/18/2010WO2010029435A1 Pd-1 specific antibodies and uses thereof
03/18/2010WO2010029434A1 Pd-1 specific antibodies and uses thereof
03/18/2010WO2010029130A1 Neuronal viability factor and use thereof
03/18/2010WO2010028798A1 Multivalent antibodies
03/18/2010WO2010028797A1 Multivalent antibodies
03/18/2010WO2010028796A1 Trispecific hexavalent antibodies
03/18/2010WO2010028795A1 Multivalent antibodies
03/18/2010WO2010028791A1 Display library for antibody selection
03/18/2010WO2010010549A3 Methods of altering peripheral b cell populations and uses thereof
03/18/2010WO2010010469A3 Amyloid beta (x - 38.. 43) oligomers, and processes, compositions, and uses thereof
03/18/2010WO2009139930A3 Antibodies and processes for preparing the same
03/18/2010WO2009137758A3 Igf-ii/gf-iie binding proteins
03/18/2010WO2009131605A3 Fusion partner cell line for preparation of hybrid cells expressing human antibodies
03/18/2010WO2009009045A3 Escape libraries of target polypeptides
03/18/2010WO2005042711A9 Pain-associated gene pnpg1
03/18/2010US20100071079 Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30l
03/18/2010US20100069616 Engineered antibody-nanoparticle conjugates
03/18/2010US20100069615 Regulation of Human Transmembrane Serine Protease
03/18/2010US20100069614 Antibody producing non-human mammals
03/18/2010US20100069611 Cytolethal distending toxins and detection of campylobacter bacteria using the same as a target
03/18/2010US20100069606 Tubular nanostructure targeted to cell membrane
03/18/2010US20100069571 Thioester-Terminated Water Soluble Polymers and Method of Modifying the N-Terminus of a Polypeptide Therewith
03/18/2010US20100069466 Compositions and Methods for the Systemic Treatment of Arthritis
03/18/2010US20100069258 Hydrophilic Labels for Biomolecules
1 ... 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 ... 1494